Work

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.

Year: 2006

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: Mark R Litzow, Sandra Lee, John M Bennett, Gordon W Dewald, Robert E Gallagher, Vibha Jain, Elisabeth M Paietta, Janis Racevskis, Steven R Rousey, Joseph J Mazza, Martin S Tallman

Institutions: Mayo Clinic, Dana-Farber Cancer Institute, University of Rochester, Yeshiva University, Marshfield Clinic, Marshfield Clinic, Marshfield Clinic, Northwestern University

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: ECOG Statistical Office Data Management Grant, EASTERN COOPERATIVE ONCOLOGY GROUP, ECOG Clinical Trials, Southwest Oncology Group, Eastern Cooperative Oncology Group, ECOG Statistical Office, Eastern Cooperative Oncology Group Operations Office

OpenAlex ID: W1833670728

FWCI: 2.666

Cites: 14

Cited by: 20

Related to: 10